INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)
NCT07341958
·
clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
242
Enrollment
OTHER
Sponsor class
Conditions
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Interventions
DRUG:
Tafolecimab
DRUG:
Placebo
Sponsor
Beijing Tiantan Hospital